1. pregnancy or breast feeding 2. alt and/or ast \> 5 x uln 3. known, active auto-immune disease; 4. ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing 5. patients with past history of solid organ transplant 6. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load 7. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours 8. patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-il-6r treatments like tocilizumab or sarilumab or anti-il-1 treatment like anakinra which should preferably be minimized 9. patients with baseline rockwood clinical frailty scale ≥ 6 at hospital admission 10. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 11. patients under guardianship

1. pregnancy or breast feeding 2. alt and/or ast \> 5 x uln 3. known, active auto-immune disease; 4. ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing 5. patients with past history of solid organ transplant 6. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load 7. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours 8. patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-il-6r treatments like tocilizumab or sarilumab or anti-il-1 treatment like anakinra which should preferably be minimized 9. patients with baseline rockwood clinical frailty scale ≥ 6 at hospital admission 10. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 11. patients under guardianship

pregnancy or breast feeding alt and/or ast > 5 x uln known, active auto-immune disease; ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing patients with past history of solid organ transplant active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-il-6r treatments like tocilizumab or sarilumab or anti-il-1 treatment like anakinra which should preferably be minimized patients with baseline rockwood clinical frailty scale ≥ 6 at hospital admission patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) patients under guardianship

pregnancy or breast feeding alt and/or ast > 5 x uln known, active auto-immune disease; ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing patients with past history of solid organ transplant active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-il-6r treatments like tocilizumab or sarilumab or anti-il-1 treatment like anakinra which should preferably be minimized patients with baseline rockwood clinical frailty scale ≥ 6 at hospital admission patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) patients under guardianship

1. pregnancy or breast feeding 2. alt and/or ast > 5 x uln 3. known, active auto-immune disease; 4. ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing 5. patients with past history of solid organ transplant 6. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load 7. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours 8. patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-il-6r treatments like tocilizumab or sarilumab or anti-il-1 treatment like anakinra which should preferably be minimized 9. patients with baseline rockwood clinical frailty scale ≥ 6 at hospital admission 10. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 11. patients under guardianship

1. pregnancy or breast feeding 2. alt and/or ast > 5 x uln 3. known, active auto-immune disease; 4. ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing 5. patients with past history of solid organ transplant 6. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load 7. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours 8. patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-il-6r treatments like tocilizumab or sarilumab or anti-il-1 treatment like anakinra which should preferably be minimized 9. patients with baseline rockwood clinical frailty scale ≥ 6 at hospital admission 10. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 11. patients under guardianship